La Jolla-based Regulus Therapeutics, a biopharmaceuticals firm developing microRNA-based medicines, said this morning that it has named Neil W. Gibson as its Chief Scientific Officer. Gibson joins the firm from PFizer, and previously has served at OSI Pharmaceuticals, Bayer, and also has served at the University of Southern California, the National Cancer Institute, and elsewhere. Regulus has major deals with GlaxoSmithKline and sanofi-aventis on various drug targets.